CJC-1295
5mg
CJC-1295 (no DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH), consisting of 29 amino acids. Research has studied its ability to increase plasma growth hormone and IGF-1 levels through sustained pulsatile release. The D-Ala modification at position 2 gives it a longer half-life than native GHRH. Often paired with Ipamorelin in GH secretagogue research. Supplied as lyophilised powder, third-party tested, lab certificate published on this page.
Published research on CJC-1295 is indexed on PubMed. See our full UK buyer's guide for CJC-1295.
Intended Use: Strictly for in-vitro laboratory research. Not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics. This product has not been evaluated by the MHRA or FDA. Buyer assumes full responsibility for safe handling and regulatory compliance.
≥98%
Purity
LAB
Certified
SAME
Day Ship
Quantity
Add £19.01 more for free UK delivery
Damaged or lost? Free reshipment guaranteed
CJC-1295 + Ipamorelin 5+5mg
Pre-blended GHRH + GHRP research peptide vial. CJC-1295 (no DAC) and Ipamorelin combined.
All components in a single lyophilised vial. One reconstitution, one inventory line, one CoA.
Research Use Only
This product is intended strictly for research and laboratory use only. Not for human consumption, medical use, or diagnostic purposes.
Certificate of Analysis
Third-party tested
Lyophilised Stability
24 months
Sealed at -20°C, light-protected
Reconstituted Stability
Up to 3 months
Stored at 2-8°C after mixing
Cold-Chain Shipping
Always
Dry-cold pack, Royal Mail Tracked 24
Important Notice
All compounds are sold individually and do not include research supplies. Products are provided in lyophilised (powder) form and require proper reconstitution before use in research settings.
Related Products
CJC-1295 Price (UK)
CJC-1295 5mg is £25.99 per vial, supplied from stock in the UK with a third-party HPLC certificate published on this page. UK delivery is £4.50 by Royal Mail Tracked 24, or free once your basket reaches £45 (£19.01 away at this price). Orders placed before 2pm on a working day are dispatched the same day.
| Vial | Price | Cost per mg | Availability |
|---|---|---|---|
| CJC-1295 5mgThis page | £25.99 | £5.20 | Low stock |
Prices are in GBP and shown per vial as supplied, lyophilised, for in-vitro laboratory research only. Cost per mg is given so researchers can compare vial sizes on a like-for-like basis. Stock and pricing on this table are read live from our inventory, so they match the basket. See our FAQ for delivery and payment options, and quality & testing for how each batch is verified.
Product Specifications
Research Overview
CJC-1295 (no DAC) is a synthetic analogue of growth hormone releasing hormone (GHRH), also referred to as modified GRF 1-29. It binds to GHRH receptors in the anterior pituitary gland to stimulate the synthesis and secretion of growth hormone. The no DAC (Drug Affinity Complex) version lacks the maleimidopropionic acid linker present in CJC-1295 with DAC, resulting in a shorter half-life that produces more pulsatile GH release patterns. Researchers consider this pulsatile pattern more physiologically similar to natural endogenous GH secretion, making CJC-1295 no DAC particularly valuable for studies requiring physiological GH release kinetics. The compound is frequently studied in combination with Ipamorelin, a selective GHS-R1a agonist, for synergistic effects through complementary receptor pathways, CJC-1295 stimulating GH release via the GHRH receptor while Ipamorelin acts at the ghrelin receptor. This dual-pathway approach produces amplified GH pulses and has become a standard research protocol in growth hormone biology. Studies have examined CJC-1295's effects on plasma GH levels, IGF-1 production, body composition, and sleep-related GH secretion patterns.
The naming around this compound is genuinely confused across the research-chemical market and is worth untangling, because it affects which papers actually apply. CJC-1295 as originally developed by ConjuChem was the DAC-bearing molecule, the drug affinity complex being the defining feature of the compound that carried that code. What is universally sold as “CJC-1295 without DAC” is more accurately tetrasubstituted GRF(1-29), a GHRH fragment carrying D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. The substitution that does the real work is D-Ala2, which blocks cleavage by dipeptidyl peptidase-4, the protease that degrades native GHRH within minutes.
The practical consequence is that a good deal of literature cited for “CJC-1295 no DAC” is in fact about the DAC molecule, about mod GRF(1-29), or about native GHRH. Teichman and colleagues (J Clin Endocrinol Metab, 2006), the most frequently cited clinical work, studied the DAC-bearing version, whose sustained albumin-bound profile is not the pulsatile profile this vial produces. Researchers reading around the compound should check which molecule a given paper actually used.
Neither version holds a marketing authorisation in any jurisdiction; ConjuChem's clinical programme did not reach approval. Supplied as lyophilised powder for in-vitro laboratory research only.
Product Specifications
Laboratory Handling
- Store lyophilised vials at -20°C for long-term storage. Reconstituted CJC-1295 should be refrigerated at 2-8°C and used within 4 weeks.
- Reconstitute with bacteriostatic water using slow, gentle injection down the vial wall. Swirl to dissolve, do not shake.
- Maintain strict aseptic technique. Sterilise vial stoppers with 70% isopropyl alcohol before each needle insertion.
- Prepare single-use aliquots from reconstituted stock. Repeated freeze-thaw cycling degrades GHRH analogue peptides.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 (no DAC), also known as modified GRF 1-29, is a synthetic 29-amino-acid analogue of growth hormone releasing hormone (GHRH). It binds GHRH receptors in the anterior pituitary to stimulate growth hormone synthesis and release. The no-DAC form produces pulsatile GH secretion that more closely mimics natural physiological release than the long-acting DAC variant. Supplied as lyophilised powder for in-vitro research use only.
CJC-1295 Research Applications
CJC-1295 is studied in endocrine research examining GHRH receptor pharmacology, pulsatile GH release kinetics, IGF-1 production, and somatotroph cell biology. It is frequently combined with Ipamorelin (a GHS-R1a agonist) for synergistic GH research, with the dual-pathway approach producing amplified GH pulses standard in growth hormone biology protocols.
Reconstitution Guide
Allow vials to reach room temperature, then sterilise the rubber stopper of both the peptide vial and the bacteriostatic water vial with an alcohol swab. Slowly draw your bacteriostatic water into a sterile insulin syringe, then inject it gently down the inner glass wall of the peptide vial, never directly onto the lyophilised powder. Once added, gently swirl the vial in a slow circular motion until fully dissolved. Never shake or vortex. The solution should be clear and colourless. Label the vial with the reconstitution date and store immediately.
See our full peptide reconstitution guide and reconstitution calculator for step-by-step protocol.
Storage Instructions
Lyophilised vials should be stored at -20°C, protected from light and moisture, and remain stable for up to 24 months. Once reconstituted with bacteriostatic water, store the solution at 2-8°C (standard refrigerator) and use within approximately 3 months. For storage beyond that, prepare single-use aliquots at -20°C, where reconstituted peptide remains stable for up to 6 months. Avoid repeated freeze-thaw cycles and always handle under sterile laboratory conditions.
Frequently Asked Questions
CJC-1295
5mg · £25.99